Physician profile
Mark Everett Bickers
NPI 1710364179
$7,150.30
in general payments reported to CMS, 2019-2025
38 companies · $967 in 2025
The $967 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.28 · 2020: $524 · 2021: $1,246 · 2022: $1,246 · 2023: $1,650 · 2024: $1,503 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,065 · Education: $55.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,065.10 |
| Education | $55.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,526.82 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,019.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $603.16 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $536.88 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $514.33 | 2020-2023 | Trintellix |
| Glaxosmithkline, LLC. | $434.07 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.64 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Biohaven Pharmaceutical Holding Company Ltd. | $259.27 | 2022 | |
| Amgen INC. | $226.69 | 2020-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $209.78 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceuticals, INC. | $194.71 | 2020-2021 | |
| Exact Sciences Corporation | $183.99 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $122.77 | 2021-2024 | Vaxelis, Gardasil 9, M-M-R II |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $121.08 | 2022-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $104.88 | 2021-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bickers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.